Too Much Alone Time? Tips To Connect And Find Joy While Social Distancing
(By Allison Aubrey for NPR) We are social creatures. So it’s no surprise that quarantine fatigue has begun to set in.
Read More
Emerging Health Issues
COVID Survivors’ Blood Plasma Is A Sought-After New Commodity
(By JoNel Aleccia for Kaiser Health News) Diana Berrent learned she had tested positive for COVID-19 on a Wednesday in
Read MoreAt-Home SARS-CoV-2 Diagnostic Tests Could be a Breakthrough, But What Are the Limitations?
(By Brittni Frederiksen, Ivette Gomez, and Alina Salganicoff for Kaiser Family Foundation) The first SARS-CoV-2 diagnostic test with a home collection
Read MoreWill Antibodies After COVID-19 Illness Prevent Reinfection?
(By Richard Harris for NPR) Most people infected with the novel coronavirus develop antibodies in response. But scientists don’t know whether
Read MoreThe U.S. government contributed research to a Gilead remdesivir patent — but didn’t get credit
(By Ed Silverman for STAT) Two documents dating back to 2015 shed further light on the role the federal government
Read MoreLooking For A Path To Reopen, Employers Weigh COVID Testing Of Workers
(By Phil Galewitz for Kaiser Health News) Just a few miles from Disney World, Harris Rosen’s hotel empire is mostly
Read MoreCigna program to pay out-of-network providers for COVID-19 services
(By Morgan Haefner for Becker’s Hospital Review) Cigna will pay out-of-network providers market-based rates for treatment provided to its members with
Read MoreNursing Home Association Asks For $10 Billion In Federal Coronavirus Relief Funds
(By Ina Jaffe for NPR) With more than 11,000 resident deaths, nursing homes have become the epicenter of the COVID-19 crisis.
Read More‘Eerie’ Emptiness of ERs Worries Doctors: Where Are The Heart Attacks And Strokes?
(By Will Stone and Elly Yu for NPR) The patient described it as the “worst headache of her life.” She didn’t go
Read MoreGilead signals steps to widen global access to remdesivir for Covid-19 patients
(By Ed Silverman for STAT) Amid questions about access to remdesivir, its treatment for Covid-19, Gilead Sciences (GILD) says it
Read More